HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in ChinaGlobeNewsWire • 09/21/21
HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine TumorsGlobeNewsWire • 09/20/21
HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular LymphomaGlobeNewsWire • 09/13/21
HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in ChinaGlobeNewsWire • 09/08/21
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual ConferenceGlobeNewsWire • 09/07/21
HUTCHMED Announces Selection of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect ProgramsGlobeNewsWire • 09/06/21
HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial CancerGlobeNewsWire • 08/26/21
Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater ChinaBenzinga • 08/09/21
HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater ChinaGlobeNewsWire • 08/09/21
Hutchmed Stock Gains On Kick Starting Mid-Stage Gastric Cancer Trial With AstraZeneca's OrpathysBenzinga • 07/28/21
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric CancerGlobeNewsWire • 07/28/21
Stabilizing Actions and End of Stabilization Period in connection with the Global OfferingGlobeNewsWire • 07/23/21
Hutchmed's Stock Rises After EMA Validates Surufatinib Application For Neuroendocrine TumorsBenzinga • 07/16/21
HUTCHMED's Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines AgencyGlobeNewsWire • 07/16/21
Here's Why "Trend" Investors Would Love Betting on Hutchison China MediTech (HCM)Zacks Investment Research • 07/13/21
HUTCHMED Announces Full Exercise of the Over-allotment Option of the Global OfferingGlobeNewsWire • 07/12/21
HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in ChinaGlobeNewsWire • 07/05/21
U.S. FDA Accepts Filing of HUTCHMED's NDA for Surufatinib for the Treatment of Advanced Neuroendocrine TumorsGlobeNewsWire • 07/01/21